| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-12-30 | Tikcro Technologies (Israel) Yeda Research and Development Company (Israel) | new antibodies targeting cancer immune checkpoints | licensing R&D |
Cancer - Oncology | Licensing agreement | |
| 2014-12-29 | Gilead (USA - CA) Janssen R&D, a J&J company (USA - NJ) | combination of darunavir (Prezista®), cobicistat (Tybost®), emtricitabine and tenofovir alafenamide (TAF) | HIV-1 infection | licensing development manufacturing production commercialisation |
Infectious diseases | Licensing agreement |
| 2014-12-29 | Nestlé (Switzerland) EpiGen Consortium | collaboration |
Nutrition - Metabolic diseases | Collaboration agreement | ||
| 2014-12-26 | Ariad Pharmaceuticals (USA - MA) Otsuka Pharmaceutical (Japan) | Iclusig® (ponatinib) | rresistant and intolerant chronic myeloid leukemia (CML) and Philadelphia -chromosome positive acute lymphoblastic leukemia (Ph+ALL) | commercialisation |
Cancer - Oncology | Commercialisation agreement |
| 2014-12-26 | Acucela (USA - WA) | chief executive officer | nomination | Ophtalmological diseases | Nomination | |
| 2014-12-23 | BioLineRx (Israel) Omega Pharma (Belgium) | BL-5010 | non-surgical removal of benign skin lesions | licensing |
Dermatological diseases | Licensing agreement |
| 2014-12-23 | GSK (UK) Roivant Neurosciences (Bermuda) | SB742457 | Alzheimer\'s disease | product acquisition |
Neurodegenerative diseases | Product acquisition |
| 2014-12-23 | Astellas (Japan) Cytokinetics (USA - CA) | skeletal muscle activators including CK-2127107 | R&D development commercialisation |
Neuromuscular diseases - Rare diseases | Development agreement | |
| 2014-12-22 | Osiris Therapeutics (USA - MD ) Stryker (USA - MI) | BIO4 | development commercialisation |
Regenerative medicine | Development agreement | |
| 2014-12-22 | Eli Lilly (USA - IN) University of Surrey (UK) | type 2 diabetes | R&D |
Metabolic diseases | R&D agreement | |
| 2014-12-22 | Evotec (Germany) Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (“OSUCCC – James”) (USA - OH) | KRas target | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-12-22 | EpiVax (USA - RI) Novozymes (Denmark) | autoimmune diseases | licensing development |
Licensing agreement | ||
| 2014-12-22 | Genentech, a member of Roche Group (USA - CA - Switzerland) Phylogica (Australia) | novel antibiotics | bacterial infections | R&D licensing |
Infectious diseases | R&D agreement |
| 2014-12-22 | Novimmune (Switzerland) Tiziana Life Sciences (UK) | foralumab (NI-0401) | licensing |
Autoimmmune diseases - Digestive diseases - Inflammatory diseases - Transplantation | Licensing agreement | |
| 2014-12-19 | BTG (UK) | member of the board of directors | nomination | Nomination | ||
| 2014-12-19 | Cardiome Pharma (Canada) Eddingpharm (China) | Brinavess™ (vernakalant IV) | conversion of recent onset atrial fibrillation to sinus rhythm in adults | development commercialisation |
Cardiovascular diseases | Development agreement |
| 2014-12-19 | Alnylam Pharmaceuticals (USA - MA) | resignation |
Resignation | |||
| 2014-12-19 | AmVac (Switzerland) the Helmholtz Centre (Germany) | Malp-2 | licensing |
Cancer - Oncology - Infectious diseases | Licensing agreement | |
| 2014-12-19 | Gilead Sciences (USA - CA) Ono Pharmaceutical (Japan) | ONO-4059 | B-cell malignancies and other diseases | licensing development commercialisation |
Cancer -Oncology | Licensing agreement |
| 2014-12-18 | Alnylam Pharmaceuticals (USA - MA) | member of the board of directors | nomination | Nomination |
